ReviewClinical medicine (London, England)2023
The weight of obesity in hypertrophic cardiomyopathy.
Review in Clinical medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Efficacy and safety of exercise for hypertrophic cardiomyopathy: a systematic review and meta-analysis.Proceedings (Baylor University. Medical Center) · 2026Pooled it
- Vascular changes in hypertrophic cardiomyopathy.Cardiovascular research · 2026Review
- Exercise Rehabilitation for Heart Failure and Associated Cardiomyopathies.Current cardiology reports · 2025Review
- Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy.JAMA cardiology · 2025Article
- Anti-Obesity, Lipid-Lowering, and Anti-Hyperglycemic Effects of CB-02 in High-Fat-Diet-Induced Obese Mice.Molecules (Basel, Switzerland) · 2025Article
- Study on the Regulated Cell Death of Hypertrophic H9c2 Cells Induced by Au:Ag Nanoparticles.International journal of nanomedicine · 2025Article
- Gender differences in the relationship between cardiometabolic index and all-cause and specific mortality in the United States adults: a national study.Frontiers in endocrinology · 2025Article
- Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.Biomedicines · 2024Review
- Morphology of human sinoatrial node and its surrounding right atrial muscle in the global obesity pandemic-does fat matter?Frontiers in medicine · 2024Article
- Tough on crime, tough on the causes of crime.Clinical medicine (London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy is one of the most frequently diagnosed primary conditions of the heart muscle. It is considered to be inherited, caused by genetic mutations encoding for sarcomere proteins. The marked heterogeneity in clinical manifestations and natural course of the disease, even among family members sharing the same genetic mutation, has raised the question of non-genetic environmental factors contributing to the phenotype. Obesity has been associated with worse cardiovascular outcomes in the general population. Its prevalence is increased in hypertrophic cardiomyopathy, and the two conditions share some similar pathophysiological and clinical characteristics. In this review, we aim to summarise the effects of obesity in the cardiac phenotype, the symptoms and management in patients with hypertrophic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.